Compare Adhi Karya Persero Tbk (ADHI) vs Dharma Polimetal Tbk. (DRMA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adhi Karya Persero Tbk vs Dharma Polimetal Tbk. — how do they compare? Adhi Karya Persero Tbk trades at Rp155 (market cap 1.34T, 4.62M 24h volume), while Dharma Polimetal Tbk. trades at Rp900 (market cap 4.24T, 1.6M 24h volume). The key difference: Dharma Polimetal Tbk. is far larger — about 3.2× Adhi Karya Persero Tbk's market cap, and Adhi Karya Persero Tbk is more actively traded (4.62M versus 1.6M). Which is the better fit depends on your goals.
| ADHI | DRMA | |
|---|---|---|
Market Cap | 1.34T | 4.24T |
Volume | 4.62M | 1.6M |
Lot | 46.25K | 16.04K |
Turnover | 723.23M | 1.45B |
Average Price | 156.39 | 901.1 |
Value | 723.23M | 1.45B |
Indicative Equilibrium Price | 155 | 900 |
Indicative Equilibrium Volume | 3.38K | 200 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adhi Karya Persero Tbk
The name of Adhi karya for the first time was stated in Decree of the Minister of Public Works and Labor on March 11, 1960. Subsequently, based on Government Regulation No. 65 of 1961, Adhi Karya was determined as a State Owned Company Adhi Karya. In the same year, based on the same Government Regulation, a former Dutch-owned construction company that has been nationalized, Associate NV, was merged into the Company. PT Adhi Karya (Persero) Tbk was established on Jun 1, 1974.
Read more on ADHI →About Dharma Polimetal Tbk.
PT Dharma Polimetal Tbk (“the Company”) was established in the Republic of Indonesia on 27 March based on Notarial deed No. 74 of Rukmasanti Hardjasatya, S.H. The Company begin opertions on year 1989 and commenced its commercial activities since 1990. The Company’s Majority shareholder is PT Dharma Inti Anugerah, established in Republic Indonesia on 20 November 2003.
Read more on DRMA →
